The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | M | Musculo-skeletal system | |
2 | M01 | Antiinflammatory and antirheumatic products | |
3 | M01A | Antiinflammatory and antirheumatic products, non-steroids | |
4 | M01AE | Propionic acid derivatives |
Code | Title | |
---|---|---|
M01AE01 | Ibuprofen | |
M01AE02 | Naproxen | |
M01AE03 | Ketoprofen | |
M01AE04 | Fenoprofen | |
M01AE05 | Fenbufen | |
M01AE06 | Benoxaprofen | |
M01AE07 | Suprofen | |
M01AE08 | Pirprofen | |
M01AE09 | Flurbiprofen | |
M01AE10 | Indoprofen | |
M01AE11 | Tiaprofenic acid | |
M01AE12 | Oxaprozin | |
M01AE13 | Ibuproxam | |
M01AE14 | Dexibuprofen | |
M01AE15 | Flunoxaprofen | |
M01AE16 | Alminoprofen | |
M01AE17 | Dexketoprofen | |
M01AE18 | Naproxcinod | |
M01AE51 | Ibuprofen, combinations | |
M01AE52 | Naproxen and esomeprazole | |
M01AE53 | Ketoprofen, combinations | |
M01AE56 | Naproxen and misoprostol | |
M01AE57 |
Active Ingredient | Description | |
---|---|---|
Dexibuprofen |
Dexibuprofen is considered to be the pharmacologically active enantiomer of racemic ibuprofen. Racemic ibuprofen is a non-steroidal substance with antiinflammatory and analgesic effects. Its mechanism of action is thought to be due to inhibition of prostaglandin synthesis. |
|
Dexketoprofen |
Dexketoprofen belongs to the non-steroidal anti-inflammatory group of drugs. The mechanism of action of Dexketoprofen is related to the reduction of prostaglandin synthesis by the inhibition of cyclooxygenase pathway. Furthermore, the inhibition of the synthesis of prostaglandins could affect other inflammation mediators such as kinins, causing an indirect action which would be additional to the direct action. |
|
Fenoprofen |
Fernoprofen has analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of prostaglandin synthesis. Its mode of action may be due to a decrease of prostaglandins in peripheral tissues. |
|
Flurbiprofen |
Flurbiprofen is a propionic acid derivative NSAID which acts through inhibition of prostaglandin synthesis. In humans flurbiprofen has potent analgesic, antipyretic and anti-inflammatory properties. |
|
Ibuprofen |
Ibuprofen is a propionic acid derivative NSAID that has demonstrated its efficacy by inhibition of prostaglandin synthesis. In humans ibuprofen reduces inflammatory pain, swellings and fever. Furthermore, ibuprofen reversibly inhibits platelet aggregation. |
|
Ketoprofen |
Ketoprofen is a non-steroidal anti-inflammatory drug. It has anti-inflammatory and analgesic actions. |
|
Naproxen |
Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis. |
|
Oxaprozin |
Oxaprozin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of oxaprozin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). |
|
Suprofen |
|
|
Tiaprofenic acid |
Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, especially arthritic pain. Results of in-vitro experiments and ex-vivo studies suggest a neutral or possibly beneficial effect of tiaprofenic acid on joint cartilage under experimental conditions. |
|
Zaltoprofen |
|
Title | Information Source | Document Type | |
---|---|---|---|
ADVIL LIQUI-GELS Liquid capsule | Health Products Regulatory Authority (ZA) | MPI, Generic | |
ALEVE Caplet / Capsule / Tablet | Health Products and Food Branch (CA) | MPI, CA: SPM | |
ALGIDRIN PEDIATRIC Oral suspension | Medicines Authority (MT) | MPI, EU: SmPC | |
BRUFEN 400 mg Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CALPROFEN Oral suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FENPAED Oral suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IBUGESIC Film-coated tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
IBUPROFEN 400mg Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IBUPROFEN 600mg Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
KERAL Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
KERAL Solution for injection/infusion | Medicines Authority (MT) | MPI, EU: SmPC | |
KETESSE Film-coated tablets | Health Products Regulatory Authority (ZA) | MPI, Generic | |
MOTRIN Tablet | Health Products and Food Branch (CA) | MPI, CA: SPM | |
NAPROREX Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
NAPROSYN Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
NAPROSYN, EC-NAPROSYN, ANAPROX DS Tablet, Delayed-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
NUROFEN Coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
NUROFEN DURANCE Medicated plaster | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
NUROFEN PLUS Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
NUROMOL Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
OKITASK Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ORUDIS SR Capsule | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
ORUVAIL Controlled release capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ORUVAIL Gel | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PEROFEN Coated / Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
RUPAN FEMME Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
SERACTIL Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
STIRLESCENT Effervescent tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SUDAFED NOSE SPRAY Aqueous solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SURGAM Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TEFIN Suppository | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
VIMOVO Delayed release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |